Evidence map›Paper›PMID 41088886›Full record

ArticleJournal of medicinal chemistry2025

Preclinical Evaluation of

Zerong Wang, Xiaoyu Pan, Ye Li, Fengsheng Zhang, Linjie Bian, Jindian Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zerong WangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaoyu PanDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Ye LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Fengsheng ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Linjie BianDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jindian LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0009-0004-1113-6760

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chondroitin sulfate proteoglycan 4 (CSPG4) is highly expressed in various solid tumors and promotes tumor progression and migration. Targeting CSPG4 therapy, such as monoclonal antibodies 9.2.27 and CAR-M, has already been in clinical trials. Database analysis further correlated elevated levels of CSPG4 with reduced overall survival in both cancers. Achieving real-time visualization of aberrant CSPG4 expression in various solid tumors remains a critical issue that needs to be addressed. To address this, we pioneered the preparation of three

Indexed as

Gallium RadioisotopesPancreatic NeoplasmsPeptidesPositron Emission Tomography Computed TomographyRadiopharmaceuticalsStomach NeoplasmsAnimalsCell Line, TumorFemaleHumansMiceMice, NudeTissue DistributionGallium-68Gallium RadioisotopesPeptidesRadiopharmaceuticals

Identifiers

PMID41088886
PMCPMC12622365

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.